ICD-10 Code E61.2: Magnesium Deficiency (Hypomagnesemia)

Key Takeaways

E61.2 is the only ICD-10 code for magnesium deficiency

Hypomagnesemia defined as serum magnesium below 1.7 mg/dL

Commonly occurs with hypocalcemia and hypokalemia

Documentation must include lab values and clinical context

ICD-10 Code E61.2: Understanding Magnesium Deficiency

ICD-10 Code E61.2 identifies magnesium deficiency, clinically known as hypomagnesemia. This diagnostic code applies when serum magnesium levels fall below the normal range of 1.7 to 2.2 mg/dL. Healthcare providers use E61.2 to document, track, and bill for patients presenting with low magnesium levels confirmed through laboratory testing.

Magnesium plays a critical role in over 300 enzymatic reactions, including protein synthesis, muscle function, blood pressure regulation, and glucose control. When deficiency occurs, patients may experience muscle cramps, cardiac arrhythmias, tetany, or seizures. The condition frequently accompanies other electrolyte disturbances, particularly hypocalcemia and hypokalemia, requiring comprehensive electrolyte assessment.

E61.2 sits within the ICD-10-CM chapter covering endocrine, nutritional, and metabolic diseases (E00-E89). According to the Centers for Medicare & Medicaid Services ICD-10 coding guidelines, this code requires documented evidence of low serum magnesium through laboratory confirmation. Clinical suspicion alone does not justify code assignment. For practices managing patients with electrolyte imbalances, integrated lab management software streamlines documentation workflows and ensures accurate coding.

Clinical Definition and Diagnostic Criteria for ICD-10 Code E61.2

Hypomagnesemia is defined as serum magnesium concentration below 1.7 mg/dL (.70 mmol/L). Normal reference ranges typically span 1.7 to 2.2 mg/dL, though specific laboratories may use slightly different thresholds. Severity classification depends on the degree of deficiency: mild (1.2-1.6 mg/dL), moderate (.8-1.1 mg/dL), and severe (below 0.8 mg/dL).

The World Health Organization ICD-10 classification categorises E61.2 under deficiency of mineral elements. Diagnosis requires laboratory confirmation through serum magnesium measurement. Twenty-four-hour urinary magnesium excretion or magnesium loading tests may provide additional diagnostic information in complex cases, particularly when total body magnesium depletion exists despite normal serum levels.

Clinical presentation varies widely. Some patients remain asymptomatic despite documented low levels. Others experience neuromuscular irritability manifesting as tremors, muscle fasciculations, or positive Chvostek and Trousseau signs. Cardiac manifestations include ventricular arrhythmias, particularly torsades de pointes, and potentiation of digoxin toxicity. For clinics tracking multiple diagnostic parameters, clinical measurements tracking software provides systematic monitoring capabilities.

Laboratory Testing Requirements

Standard serum magnesium testing uses colorimetric or spectrophotometric methods. Results typically return within hours, allowing rapid clinical decision-making. Testing should occur before magnesium replacement therapy when possible, as exogenous supplementation obscures true baseline values.

Concurrent electrolyte assessment is essential. Hypomagnesemia frequently coexists with hypocalcemia and hypokalemia due to shared pathophysiological mechanisms. Magnesium deficiency impairs parathyroid hormone secretion and creates end-organ resistance to PTH, producing symptomatic hypocalcemia. Similarly, magnesium is required for adequate potassium reabsorption in renal tubules, leading to refractory hypokalaemia until magnesium is corrected.

Common Causes and Clinical Context for E61.2 Diagnosis

Gastrointestinal disorders represent the most frequent aetiology. Chronic diarrhoea, malabsorption syndromes, inflammatory bowel disease, and short bowel syndrome all impair magnesium absorption from the intestinal tract. Surgical resection of the small intestine, particularly the ileum, significantly reduces absorptive capacity.

Renal losses account for another major category. Loop diuretics and thiazide diuretics increase urinary magnesium excretion. Aminoglycoside antibiotics, amphotericin B, cisplatin, and proton pump inhibitors have all been associated with magnesium wasting. Diabetic ketoacidosis and poorly controlled diabetes mellitus cause osmotic diuresis with secondary magnesium depletion.

Inadequate dietary intake rarely causes isolated hypomagnesemia in developed countries but may contribute when combined with other factors. Alcoholism deserves particular mention as it combines poor nutritional intake, impaired gastrointestinal absorption, and increased renal losses. Elderly patients and those with restricted diets face higher risk.

Medication-Induced Hypomagnesemia

Proton pump inhibitors have emerged as a significant contributor to magnesium deficiency, particularly with long-term use. The mechanism involves decreased intestinal magnesium absorption through impaired active transport. The CMS coding guidance supports documenting drug-induced electrolyte disturbances when the medication relationship is established.

Diuretic therapy requires ongoing monitoring. Patients receiving loop diuretics for heart failure or oedema management should undergo periodic magnesium assessment. Those on multiple medications affecting electrolyte balance need comprehensive metabolic panels at regular intervals.

Use Additional Code: Drug-Induced Adverse Effect

Per ICD-10-CM tabular instructions for the E61 category: Use additional code for adverse effect, if applicable, to identify drug (T36–T50 with fifth or sixth character 5).

This instruction is directly relevant to the medication-induced cases discussed above. When E61.2 results from a drug adverse effect — such as hypomagnesemia caused by long-term PPI use, loop diuretics, or cisplatin — coders must also assign the appropriate T-code from the T36–T50 range with a fifth or sixth character of 5 (indicating adverse effect). For example:

• PPI-induced hypomagnesemia: E61.2 + T47.1X5A (adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter) or the appropriate T47.- code
• Loop diuretic-induced hypomagnesemia: E61.2 + T50.1X5A (adverse effect of loop diuretics, initial encounter)
• Cisplatin-induced hypomagnesemia: E61.2 + T45.1X5A (adverse effect of antineoplastic drugs, initial encounter)

Omitting the T-code when a drug is responsible for the deficiency constitutes incomplete coding. It also misses an opportunity to document drug adverse effects that contribute to pharmacovigilance data and may affect payer medical necessity review.

Documentation Requirements for ICD-10 Code E61.2

Complete clinical documentation must include the laboratory value demonstrating hypomagnesemia, the date of testing, and the reference range used by the testing laboratory. Recording “low magnesium” without numerical values creates ambiguity and may trigger payer queries.

Clinical context strengthens documentation. Note whether the patient presents with symptoms consistent with magnesium deficiency (muscle cramps, cardiac arrhythmias, tetany) or if the finding emerged during routine metabolic screening. Document potential contributing factors such as chronic diarrhoea, diuretic use, or malabsorption disorders.

Concurrent electrolyte abnormalities require separate codes. When hypocalcemia coexists, assign E83.51 (Hypocalcemia) alongside E61.2. Similarly, document hypokalaemia with E87.6 when present. This multi-code approach accurately reflects the clinical complexity and supports appropriate reimbursement for comprehensive electrolyte management. Practices using AI-powered clinical documentation tools can automate the capture of these interrelated diagnostic elements from clinical notes.

Treatment Plans and Follow-Up Documentation

Document the treatment approach, whether oral supplementation or intravenous replacement. Include the specific magnesium formulation (magnesium oxide, magnesium citrate, magnesium sulphate), dose, route, and frequency. Note any adjustments based on renal function, as impaired kidney function requires dose modification.

Follow-up laboratory monitoring demonstrates appropriate clinical management. Schedule repeat magnesium levels based on deficiency severity and replacement route. Intravenous therapy typically requires more frequent monitoring than oral supplementation. Document trending values to establish treatment efficacy and guide ongoing management.

Related ICD-10 Codes and Differential Diagnosis

E61.2 is the code for magnesium deficiency in a nutritional context, but it is not the only ICD-10-CM code for low magnesium. E83.42 (Hypomagnesemia) also exists under disorders of magnesium metabolism (E83) for cases where the cause is metabolic rather than nutritional. See the E61.2 vs E83.42 section below for guidance on when to use each code.

Related electrolyte disorders that frequently accompany E61.2 include E83.51 (Hypocalcemia), E87.6 (Hypokalaemia), and E87.1 (Hypo-osmolality and hyponatraemia). These conditions often cluster in patients with gastrointestinal losses, renal disease, or medication effects. The ICD List reference database provides comprehensive crosswalking between related electrolyte disorder codes.

When coding for symptoms potentially attributable to hypomagnesemia, consider whether the laboratory-confirmed diagnosis renders symptom codes unnecessary. Documented E61.2 with abnormal lab values typically supersedes non-specific codes for muscle cramps (R25.2) or cardiac arrhythmias (I49.9) when the electrolyte disturbance explains the presentation.

E61 Category: Excludes1 Notes

The E61 parent category carries Excludes1 notes — conditions that cannot be coded simultaneously with any E61 code, including E61.2. If any of the following are the correct characterisation of the patient’s condition, use those codes instead of E61.2:

• Disorders of mineral metabolism (E83.-) — including E83.42 (Hypomagnesemia under metabolic disorders); see the E61.2 vs E83.42 section below
• Iodine deficiency related thyroid disorders (E00–E02)
• Sequelae of malnutrition and other nutritional deficiencies (E64)

Within the E61.x subcategory, distinguish E61.2 from adjacent codes: E61.1 identifies iron deficiency, E61.3 covers zinc deficiency, and E61.8 captures deficiency of other specified nutrient elements. These codes are not interchangeable despite occupying adjacent positions in the classification system.

Hypermagnesaemia receives a separate code (E83.41). Confusing hypo- and hypermagnesaemia creates clinical risk and billing errors. For practices managing complex endocrine and metabolic conditions, functional medicine software supports accurate documentation of nuanced diagnostic patterns.

E61.2 vs E83.42: Choosing the Correct Hypomagnesemia Code

This is one of the most common hypomagnesemia coding confusion points. Two ICD-10-CM codes can describe low magnesium — and the E61 category Excludes1 note makes them mutually exclusive:

In practice, the distinction follows the documented aetiology. A hospitalised patient with hypomagnesemia from Gitelman syndrome (a renal tubular disorder causing urinary magnesium wasting) should be coded E83.42. A patient with hypomagnesemia from short bowel syndrome and poor oral intake should be coded E61.2. When the aetiology is unclear or involves both nutritional and metabolic factors, query the physician before assigning either code, as the Excludes1 note prevents using both simultaneously.

Streamline electrolyte disorder documentation

Automate lab result integration, flag abnormal values, and generate compliant diagnostic coding for complex metabolic conditions. See how Pabau supports precise clinical documentation workflows.

Book a demo

Billing and Reimbursement Considerations for E61.2

E61.2 functions as a billable diagnosis code when documented with laboratory confirmation. Payers typically accept this code for office visits, inpatient encounters, and laboratory interpretation services. Reimbursement depends on the complexity of the overall clinical presentation and associated comorbidities.

When hypomagnesemia occurs as part of a broader metabolic derangement, it may not serve as the principal diagnosis. Assign it as a secondary code alongside the primary condition (such as diabetic ketoacidosis or inflammatory bowel disease) to capture the complete clinical picture. This approach supports higher-level evaluation and management coding when warranted.

Laboratory testing related to E61.2 includes serum magnesium measurement (typically billed under CPT 83735), comprehensive metabolic panels, and specialised testing for renal magnesium handling. Document the medical necessity for each test ordered. Routine screening without clinical indication may face coverage denial.

MS-DRG Grouping for Inpatient E61.2 Billing

For inpatient hospital billing, E61.2 groups to the following Medicare Severity Diagnosis-Related Groups (MS-DRGs):

• MS-DRG 640 — Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCC (Major Complication or Comorbidity)
• MS-DRG 641 — Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes without MCC

The MCC designation significantly affects reimbursement. Inpatient coders should ensure all major complications and comorbidities present during the admission are documented and coded — for example, acute kidney injury, sepsis, or heart failure alongside hypomagnesemia — as these determine whether the case groups to DRG 640 (higher reimbursement) or DRG 641. Query the attending physician if MCC conditions are clinically evident in the record but not explicitly documented.

Common Documentation Errors to Avoid

Avoid assigning E61.2 based solely on clinical symptoms without laboratory confirmation. Payers require objective evidence of low magnesium levels. Document the specific serum magnesium value and testing date to support code assignment.

Do not use E61.2 for patients receiving prophylactic magnesium supplementation without demonstrated deficiency. Preventive supplementation in high-risk populations (such as those on chronic diuretics) requires different coding unless laboratory testing confirms hypomagnesemia.

Recording “electrolyte imbalance” without specifying which electrolyte is deficient creates documentation gaps. Use precise codes (E61.2 for magnesium, E87.6 for potassium, E83.51 for calcium) rather than non-specific codes like E87.8 (Other disorders of electrolyte and fluid balance). Practices using structured digital intake forms capture specific electrolyte values systematically, reducing coding ambiguity.

Clinical Management and Treatment Documentation

Treatment approaches depend on deficiency severity and clinical presentation. Asymptomatic mild hypomagnesemia (1.2-1.6 mg/dL) typically responds to oral magnesium supplementation. Magnesium oxide provides the highest elemental magnesium content but has lower bioavailability compared to magnesium citrate or magnesium chloride.

Severe or symptomatic deficiency requires intravenous magnesium sulphate. Standard protocols deliver 1-2 grams over 15-60 minutes for acute symptomatic cases, followed by continuous infusion or repeated boluses based on clinical response and serial magnesium measurements. Cardiac monitoring is essential during IV magnesium administration due to potential conduction effects.

Refractory hypokalaemia that fails to respond to potassium supplementation suggests concurrent magnesium deficiency. In these cases, correcting magnesium is essential before potassium normalisation can occur. Document the clinical reasoning when initiating magnesium therapy for patients with resistant hypokalaemia even if serum magnesium appears normal.

Addressing Underlying Causes

Effective management requires identifying and addressing root causes. Patients with chronic diarrhoea need gastrointestinal evaluation. Those on long-term PPI therapy should undergo periodic reassessment of medication necessity. Diuretic-induced losses may respond to potassium-sparing diuretic addition or dose reduction when clinically feasible.

Alcoholism requires comprehensive intervention beyond simple magnesium replacement. Document referrals to addiction services, nutritional counselling, and psychiatric support when alcohol use contributes to electrolyte disturbances. This demonstrates appropriate response to the underlying pathology rather than isolated symptom management.

For patients requiring ongoing monitoring across multiple specialties, unified patient record systems ensure all providers access current laboratory data and treatment plans. This coordination prevents duplicate testing and conflicting therapeutic approaches.

Special Populations and Clinical Considerations

Pregnancy increases magnesium requirements, with recommended dietary allowances rising from 310-320 mg/day to 350-360 mg/day. Pre-eclampsia management routinely involves intravenous magnesium sulphate for seizure prophylaxis, distinct from treatment of deficiency. Document the indication clearly when coding magnesium administration during pregnancy.

Elderly patients face higher risk due to reduced dietary intake, decreased intestinal absorption, and increased medication use. Age-related decline in renal function affects both magnesium homeostasis and safe supplementation dosing. Calculate creatinine clearance before prescribing high-dose magnesium to avoid toxicity in patients with renal impairment.

Critically ill patients frequently develop hypomagnesemia from multiple concurrent factors including diuretic use, antibiotic therapy, and acute inflammatory states. ICU protocols often include routine magnesium monitoring and aggressive replacement given the association between low magnesium and increased morbidity, particularly cardiac complications.

Chronic Disease Management

Diabetes mellitus creates ongoing magnesium loss through glucosuria and osmotic diuresis. Insulin resistance may worsen with magnesium deficiency, creating a bidirectional relationship. Diabetic patients require regular magnesium screening as part of comprehensive metabolic assessment. For diabetes-focused practices, metabolic health EMR systems track these interconnected laboratory parameters systematically.

Heart failure patients receiving loop diuretics need vigilant electrolyte monitoring. Hypomagnesemia increases the risk of ventricular arrhythmias and sudden cardiac death in this population. Some guidelines recommend maintaining magnesium levels above 2.0 mg/dL in heart failure patients, higher than the standard lower reference limit.

Expert Picks

Managing patients with chronic metabolic conditions? Integrative Medicine Software supports comprehensive tracking of laboratory trends, supplement protocols, and multi-system therapeutic approaches.

Need streamlined laboratory result integration? Lab Management Software automatically imports test results, flags abnormal values, and links findings to relevant patient encounters for complete documentation.

Coordinating care for complex electrolyte disorders? Primary Care Software centralises diagnostic data, treatment plans, and follow-up scheduling across multiple providers managing interconnected conditions.

Conclusion

ICD-10 Code E61.2 provides precise classification for magnesium deficiency when serum levels fall below 1.7 mg/dL. Accurate documentation requires laboratory confirmation, clinical context noting symptoms or risk factors, and comprehensive recording of concurrent electrolyte abnormalities. The code supports appropriate reimbursement when medical necessity is established through thorough clinical documentation.

Effective management extends beyond simple supplementation to address underlying causes such as medication effects, gastrointestinal disorders, or renal losses. Regular monitoring ensures treatment efficacy and identifies patients requiring ongoing intervention. Integrated clinical systems streamline laboratory tracking, automate abnormal value flagging, and facilitate coordinated care across specialties managing complex metabolic conditions.

Frequently Asked Questions